Completed PHASE3 INTERVENTIONAL 2-arm NCT01796262

The Effects of DHA on Attention Deficit and Hyperactivity Disorder (DADA)

The Effects of DHA (DOCOSAHEXAENOIC ACID) on Attention Deficit and Hyperactivity Disorder

Sponsor: DMF srl (Dietetic Metabolic Food)

Conditions Attention Deficit Hyperactivity Disorder

Interventions Wheat germ oil docosahexaenoic acid

Updated 6 times since 2017 Last updated: Feb 25, 2020 Started: Jun 30, 2012 Primary completion: Feb 28, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Attention Deficit Hyperactivity Disorder and is currently completed. DMF srl (Dietetic Metabolic Food) leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Mar 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Mar 2020 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

DMF srl (Dietetic Metabolic Food)
IRCCS Eugenio Medea

Data source: IRCCS Eugenio Medea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bosisio Parini, Italy